



Potential List of Drugs Selected for IRA Negotiation in 2027 (Top 20)

Drug	Company	Drug Class	2022 CMS Spend (\$M)	Est. 2026 US Sales (\$M)	Est. % Medicare Exposure	US LOE	Select Competitors (2022 CMS Spend \$M)				
Ozempic		GLP-1	\$4,628	\$18,000	~30%	2032	Trulicity (\$6,225) 	Victoza (\$1,558) 	Bydureon (\$356) 	Mounjaro (\$144) 	
Trelegy Elipta		LAMA + LABA + ICS	\$3,340	\$3,800	~25%	2027	Symbicort (\$1,965) 	Breztri (\$459) 	Spiolto (\$387) 		
Xtandi		Anti-androgens	\$2,437	\$2,400	~80%	2027	Erleada (\$878) 	Nubeqa (\$322) 	Zytiga (\$54) 		
Invega		Antipsychotics	\$2,161	\$3,500	~35%	2031	Vraylar (\$709) 	Abilify (\$577) 	Rexulti (\$490)   	Caplyta (\$108)  Lybalvi (\$39) 	
Ibrance		CDK 4/6 inhibitors	\$1,948	\$2,500	~40%	2027	Verzenio (\$474) 	Kisqali (\$181) 	Trodelvy (\$3) 		
Humalog / Insulin Lispro		Rapid-acting insulin	\$1,944	N/A	N/A	2026	Novolog (\$2,810) 	Fiasp (\$87) 	Afrezza (\$13) 	Apidra (\$12) 	
Ofev		Kinase inhibitors	\$1,763	\$3,500	~60%	2029	Esbriet (\$410) 				
Pomalyst		Antineoplastics	\$1,744	\$400	~45%	2027	Revlimid (\$5,935) 				
Linzess		Guanylate cyclase-C	\$1,582	\$1,200	~50%	2026	Motegrity (\$49) 	Amitiza (\$23) 	Trulance (\$1) 		
Victoza		GLP-1	\$1,558	\$350	~15%	2023	Trulicity (\$6,225) 	Ozempic (\$4,628) 	Bydureon (\$356) 	Mounjaro (\$144) 	
Breo Elipta		LABA	\$1,428	\$1,000	~25%	2025	Symbicort (\$1,965) 	Striverdi (\$5) 			
Tradjenta	 	DPP-4 inhibitors	\$1,327	\$865	~25%	2025	Januvia (\$4,098) 	Onglyza (\$91) 	Nesina (\$0.37) 		
Creon		Enzymes	\$1,311	\$1,100	~55%	2031	Pancreaze (\$8) 	Viokace (\$3) 			
Janumet		DPP-4 inhibitors	\$1,213	\$1,000	~20%	2025	Januvia (\$4,098)  	Onglyza (\$91) 	Nesina (\$0.37) 		
Calquence		BTK inhibitors	\$1,193	\$2,000	~70%	2026	Imbruvica (\$2,854) 	Venclexta (\$768) 	Brukinsa (\$303) 		
Epclusa		Antivirals	\$1,002	\$1,000	~25%	2033	Mavyret (\$235) 	Harvoni (\$78) 	Vosevi (\$50) 	Zepatier (\$0.34) 	
Xifaxan		Antibiotics	\$970	\$2,750	~60%	2027	Viberzi (\$59) 	Aemcoloi (N/A) 			
Austedo		VMAT2	\$890	\$2,100	~50%	2024	Ingrezza (\$1,273) 				
Vraylar	 	Antipsychotics	\$709	\$4,700	~35%	2029	Invega (\$2,161) 	Abilify (\$577) 	Rexulti (\$490)   	Caplyta (\$108)  Lybalvi (\$39) 	
Verzenio		CDK 4/6 inhibitors	\$474	\$4,500	~15%	2031	Ibrance (\$1,984) 	Kisqali (\$181) 	Trodelvy (\$3) 		

Note: As of 11/26/2024, **non-exhaustive**; LABA: Long-acting beta agonist; PDE4 inhibitor: phosphodiesterase 4; BTK inhibitors: Bruton tyrosine kinase; RR: Run rate; VMAT2: Vesicular monoamine transporter 2 inhibitors; Trajenta revenue includes Jentadueto